Aliri was recently one of 10 labs to participate in the Oligonucleotide Ring Trial, in which industry experts joined together to evaluate the effectiveness of LC-MS, LBA, and qPCR when quantifying the concentrations of oligonucleotide in biological samples. This first-of-its-kind study aimed to give clarity to drug developers about the methodology best suited for future development programs. Specifically, the Ring Trial focused on three types of oligonucleotides, an ASO (Fomivirsen), a GalNAc-siRNA (Lumasiran), and a PMO (Viltolarsen).
Troy Voelker, Sr. Lab Director at Aliri and Chair of the AAPS Oligonucleotide Discussion Group, led the LC-MS method development of the PMO (Viltolarsen), which was analyzed using three mass spectrometry platforms: a QExactive, a time-of-flight (TOF), and a triple quadrupole instrument. In this presentation, he reveals exciting data that proves hybridization LC-MS superior to LBA in achieving lower detection limits and higher specificity.
Download the presentation to read the study findings.